TYK Medicines, Inc. (Ticker: 02410.HK) is a biotechnology company focused on the discovery, development, and commercialization of targeted therapies for cancer treatment. The company will list on the Main Board of The Stock Exchange of Hong Kong on August 20, 2024.

TYK Medicines is offering 4,788,000 shares at an offer price of HKD 12.10 per share. The expected market capitalization at the time of listing is approximately HKD 4.49 billion (USD 574 million). The total offer size is HKD 57.92 million (USD 74.33 million).

The offering is managed by CITIC Securities (Hong Kong) Limited, with underwriting by CLSA Limited, Deutsche Bank AG, Hong Kong Branch, and several others. The proceeds will be used for R&D, product capacity expansion, brand promotion, business development, working capital, and strategic acquisitions.